[go: up one dir, main page]

MX2022004785A - Metodos y composiciones para el tratamiento del sindrome de rett. - Google Patents

Metodos y composiciones para el tratamiento del sindrome de rett.

Info

Publication number
MX2022004785A
MX2022004785A MX2022004785A MX2022004785A MX2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A MX 2022004785 A MX2022004785 A MX 2022004785A
Authority
MX
Mexico
Prior art keywords
methods
rett syndrome
compositions
treatment
trofinetide
Prior art date
Application number
MX2022004785A
Other languages
English (en)
Inventor
Mona Darwish
James M Youakim
Lawrence Irwin Glass
Nancy Elizabeth Jones
Sean Paul Oosterholt
Oscar Della Pasqua
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of MX2022004785A publication Critical patent/MX2022004785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

En la presente se divulgan métodos de tratamiento del síndrome de Rett que comprenden administrar trofinetide a un sujeto que lo necesita en los que se proporciona una dosificación que puede reducir o evitar una subexposición, p. ej., en sujetos de peso corporal bajo, y/o proporcionar otros beneficios.
MX2022004785A 2019-10-28 2020-10-28 Metodos y composiciones para el tratamiento del sindrome de rett. MX2022004785A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927008P 2019-10-28 2019-10-28
US202063031201P 2020-05-28 2020-05-28
PCT/US2020/057627 WO2021086892A1 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of rett syndrome

Publications (1)

Publication Number Publication Date
MX2022004785A true MX2022004785A (es) 2022-05-16

Family

ID=75715568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004785A MX2022004785A (es) 2019-10-28 2020-10-28 Metodos y composiciones para el tratamiento del sindrome de rett.

Country Status (14)

Country Link
US (1) US20220339138A1 (es)
EP (1) EP4051308A4 (es)
JP (2) JP2022553888A (es)
KR (1) KR20220106982A (es)
CN (1) CN115335071A (es)
AU (1) AU2020376801A1 (es)
BR (1) BR112022008095A2 (es)
CA (1) CA3156680A1 (es)
CL (1) CL2022001079A1 (es)
CO (1) CO2022007501A2 (es)
IL (1) IL292617B1 (es)
MX (1) MX2022004785A (es)
TW (1) TW202116300A (es)
WO (1) WO2021086892A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117460415A (zh) 2021-07-12 2024-01-26 阿卡蒂亚药品公司 曲非奈肽的结晶形式
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
WO2025262646A1 (en) * 2024-06-22 2025-12-26 Biophore India Pharmaceuticals Pvt. Ltd Dosage forms of trofinetide and its pharmaceutically acceptable salt thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6709817B1 (en) * 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
BR112013018898B1 (pt) * 2011-01-27 2021-10-05 Neuren Pharmaceuticals Limited Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
CA2899602C (en) * 2013-02-20 2024-01-30 Theravasc Inc. Pharmaceutical uses of inorganic nitrites
RS60679B1 (sr) * 2013-07-25 2020-09-30 Neuren Pharmaceuticals Ltd Neurozaštitna biciklična jedinjenja i postupci za njihovu upotrebu u lečenju poremećaja iz spektra autizma i neurorazvojnih poremećaja
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
GB2554064B (en) * 2016-09-01 2019-11-20 Jit Singh Shailinder An enteral feeding tube

Also Published As

Publication number Publication date
KR20220106982A (ko) 2022-08-01
JP2022553888A (ja) 2022-12-26
US20220339138A1 (en) 2022-10-27
EP4051308A1 (en) 2022-09-07
CO2022007501A2 (es) 2022-08-30
CN115335071A (zh) 2022-11-11
WO2021086892A1 (en) 2021-05-06
TW202116300A (zh) 2021-05-01
IL292617B1 (en) 2025-11-01
BR112022008095A2 (pt) 2022-07-12
AU2020376801A1 (en) 2022-06-09
IL292617A (en) 2022-07-01
EP4051308A4 (en) 2023-08-23
JP2025148461A (ja) 2025-10-07
CA3156680A1 (en) 2021-05-06
CL2022001079A1 (es) 2023-04-21

Similar Documents

Publication Publication Date Title
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12020551427A1 (en) Epinephrine spray formulations
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.